Marine Biotechnology Laboratory, State Key Laboratory of Microbial Metabolism and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
Appl Microbiol Biotechnol. 2018 Sep;102(18):7865-7875. doi: 10.1007/s00253-018-9237-5. Epub 2018 Jul 23.
BC194, a derivative of borrelidin (BN) that features a lower cytotoxicity than that of BN due to an altered starter unit, trans-1,2-cyclobutanedicarboxylic acid (trans-1,2-CBDA), is a potent inhibitor of angiogenesis. However, BC194 production has only been reported to occur via mutasynthesis, which requires tedious, multistep genetic manipulation. In this study, we surveyed several factors contributing to the precursor-directed biosynthesis of BC194 and provided an alternative method for the production of BC194 that is directly applicable to other BN-producing strains. First, the precursor-directed biosynthesis of BC194 by a BN-producing strain, Streptomyces rochei MB037 derived from sponge Dysidea arenaria, was carried out in modified Radix astragali (RA) medium with 5 mM trans-1,2-CBDA. Next, possible inhibitors of BN starter unit trans-1,2-cyclopentanedicarboxylic acid (trans-1,2-CPDA) biosynthesis were investigated. It was found that potassium ferricyanide was a possible inhibitor of 3,4-dihydroxyphenylacetate 2,3-dioxygenase (DHPAO) and capable of suppressing the yield of BN and increasing the BC194 yield by 112.5% (from 5.2 ± 0.76 to 11.9 ± 0.59 mg/L). BC194 yield was further enhanced in the presence of 50 mM trans-1,2-CBDA, reaching 20.2 ± 0.62 mg/L. Furthermore, 3% macroporous adsorbent DA-201 resin was added to the fermentation broth, enabling a further 36.6% increase in BC194 production and reaching 27.59 ± 1.15 mg/L. Moreover, an efficient separation of BC194 with approximately 95% purity was developed by employing high-speed counter-current chromatography (HSCCC), achieving an improved recovery (approximately 93%).
BC194 是博莱霉素(BN)的一种衍生物,由于起始单元发生改变(由反式-1,2-环丁烷二羧酸(trans-1,2-CBDA)代替),其细胞毒性比 BN 低,是一种有效的血管生成抑制剂。然而,BC194 的生产仅通过突变合成来报道,该方法需要繁琐的多步基因操作。在这项研究中,我们调查了几种促成 BC194 前体定向生物合成的因素,并提供了一种替代方法来生产 BC194,该方法可直接应用于其他 BN 产生菌株。首先,在改良的黄芪(RA)培养基中,用 5mM 的反式-1,2-CBDA 进行 BN 产生菌罗氏链霉菌 MB037 合成 BC194。接下来,研究了 BN 起始单元反式-1,2-环戊烷二羧酸(trans-1,2-CPDA)生物合成的可能抑制剂。结果发现,铁氰化钾可能是 3,4-二羟基苯乙酸 2,3-加氧酶(DHPAO)的抑制剂,能够抑制 BN 的产量,并将 BC194 的产量提高 112.5%(从 5.2±0.76 到 11.9±0.59mg/L)。在存在 50mM 反式-1,2-CBDA 的情况下,BC194 的产量进一步提高,达到 20.2±0.62mg/L。此外,在发酵液中添加 3%大孔吸附树脂 DA-201,使 BC194 的产量进一步增加 36.6%,达到 27.59±1.15mg/L。此外,通过高速逆流色谱(HSCCC)开发了一种有效的 BC194 分离方法,纯度约为 95%,回收率提高了约 93%。